Min Hao

机构：Zhejiang Chinese Medical University, Shanxi Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming Medical University, Fuwai Yunnan Cardiovascular Hospital, Second Hospital of Shanxi Medical University · ORCID：0000-0002-5643-8920

发表论文 122 篇 · 总被引 1794 次 · h-index 24

代表论文

• Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China (2024 · The Lancet · 被引 110)
• Antimicrobial resistance of clinical bacterial isolates in China: current status and trends (2024 · JAC-Antimicrobial Resistance · 被引 107)
• Renal tubular epithelial cell quality control mechanisms as therapeutic targets in renal fibrosis (2024 · Journal of Pharmaceutical Analysis · 被引 34)
• The role of JNK signaling pathway in organ fibrosis (2024 · Journal of Advanced Research · 被引 19)
• Clinical features and risk factors for pyogenic liver abscess caused by multidrug-resistant organisms: A retrospective study (2024 · Virulence · 被引 12)
• Association of COVID-19 with thyroid dysfunction and autoimmune thyroid disease: A retrospective cohort study (2024 · Journal of Translational Autoimmunity · 被引 9)